Symptomatic Care in Multiple System Atrophy: State of the Art
- PMID: 35581488
- PMCID: PMC10125958
- DOI: 10.1007/s12311-022-01411-6
Symptomatic Care in Multiple System Atrophy: State of the Art
Abstract
Without any disease-modifying treatment strategy for multiple system atrophy (MSA), the therapeutic management of MSA patients focuses on a multidisciplinary strategy of symptom control. In the present review, we will focus on state of the art treatment in MSA and additionally give a short overview about ongoing randomized controlled trials in this field.
Keywords: Autonomic dysfunction; Motor and non-motor symptoms; Multiple system atrophy; Symptomatic treatment.
© 2022. The Author(s).
Conflict of interest statement
KS reports personal fees from Teva, UCB, Lundbeck, AOP Orphan Pharmaceuticals AG, Roche, Gruenenthal, Stada, Lucher Pharma, Biogen, BIAL, and AbbVie, and honoraria from the International Parkinson and Movement Disorders Society. All other authors declare no competing interests.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
